Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most （clusters of differentiation）CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells^[1]^[2].

References:

[1]. L Franco, et al. The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J. 1998 Nov;12(14):1507-20. [Content Brief]

[2]. Kumi Oshima, et al. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett. 2002 May 22;519(1-3):1-7. [Content Brief]

Transmembrane Glycoprotein Related Products (252):

By Effects:	Inhibitors (175) Ligands (6) Agonists (3) Antagonists (5) Activators (8) Modulators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P10495

GPR110 peptide agonist P12	Activator
GPR110 peptide agonist P12 is a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 can be used in the study of developmental disorders and cancers related to GPR110.

HY-P990317

AGS-67E	Inhibitor	99.46%
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).

HY-P990288

Anti-Mouse CD18 Antibody (M18/2)	Inhibitor
Anti-Mouse CD18 Antibody (M18/2) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD18. Anti-Mouse CD18 Antibody (M18/2) can neutralize lymphocyte function-associated antigen 1 (LFA-1). Anti-Mouse CD18 Antibody (M18/2) can be used for the researches of immunology, such as heart transplantation.

HY-P991624

Anti-UNC5B Antibody (YW88)	Inhibitor
Anti-UNC5B Antibody (YW88) is a monoclonal antibody against UNC5B. Anti-UNC5B Antibody (YW88) can inhibit the binding of Netrin-1 to Unc5B. Anti-UNC5B Antibody (YW88) can be used in research on angiogenesis.

HY-P990156

Anti-Mouse Thy1.1/CD90.1 Antibody (19E12)	Inhibitor
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) is an anti-mouse Thy1.1/CD90.1 IgG2a monoclonal antibody. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can deplete CD90.1⁺ cells. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can clear Tregs. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can be used for researches on inflammation conditions and immune response such as airway inflammation and experimental autoimmune encephalomyelitis (EAE).

HY-P99928

Efprezimod alfa
Efprezimod alfa is a CD24 fusion protein. Efprezimod alfa can be used for various biochemical studies.

HY-P990277

Anti-Mouse CD31/PECAM-1 Antibody (390)	Inhibitor
Anti-Mouse CD31/PECAM-1 Antibody (390) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD31/PECAM-1. Anti-Mouse CD31/PECAM-1 Antibody (390) reacts with mouse CD31, also known as PECAM-1 (platelet endothelial cell adhesion molecule). Anti-Mouse CD31/PECAM-1 Antibody (390) inhibits angiogenesis. Anti-Mouse CD31/PECAM-1 Antibody (390) can be used for the research of cancer, such as A549 tumor.

HY-P990166

Anti-Mouse PSGL-1/CD162 Antibody (4RA10)	Inhibitor
Anti-Mouse PSGL-1/CD162 Antibody (4RA10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse PSGL-1/CD162. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) blocks PSGL signaling and inhibits leukocyte rolling. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) can be used for the researches of inflammation, immunology and infection, such as pneumonia and lymphocytic choriomeningitis virus infection.

HY-P990123

Anti-Mouse ICOSL/CD275 Antibody (HK5.3)	Inhibitor	98.59%
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis.

HY-P990861

Anti-CD4 Antibody (OKT-4)
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human CD4. Anti-CD4 Antibody (OKT-4) can deplete T cells. Anti-CD4 Antibody (OKT-4) can be used for the researches of cancer, infection and immunology, such as melanoma and adenovirus infection.

HY-171792

BMS-986497	Inhibitor
BMS-986497 (ORM-6151) is a CD33-targeted antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells, inducing GSPT1 protein degradation. BMS-986497 is promising for research of acute myeloid leukemia (AML).

HY-157763

Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 (Compound 3) is a "linker-payload" component of an antibody-drug conjugate (ADC). Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 selectively delivers the dual-function BTK degrader to B-cell malignancies by targeting the monoclonal antibody of CD79b. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be coupled to the engineered CD79b antibody with cysteine, forming CD79b-3 ADC (ADC linker: (HY-130944); Protac: (HY-163295)).

HY-P990960

Lucorafusp alfa
HY-P990960 is an TIGIT-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990031

Dargistotug		99.36%
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.

HY-P990975

Birinkibart
HY-P990975 is an CSF2RB-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P9943

Igovomab	Inhibitor
Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research.

HY-P990853

Anti-CEACAM5 Antibody (4H11-8)	Inhibitor
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CEACAM5. Anti-CEACAM5 Antibody (4H11-8) reacts with human CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5). Anti-CEACAM5 Antibody (4H11-8) can be used for detecting CEACAM5 in cancer.

HY-P991426

MB-314	Inhibitor
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research.

HY-P991095

ALG.APV-527	Inhibitor
ALG.APV-527 (APV-527) is a bispecific 4-1BB (CD137) and 5T4 antibody. ALG.APV-527 is designed to activate 4-1BB on T and natural killer (NK) cells only when simultaneously bound to 5T4-expressing tumor cells. ALG.APV-527 has a potent antitumor activity.

HY-P991562

MDX-1411	Inhibitor
MDX-1411 is a fully human monoclonal antibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies.

Name
Email *

	Sorry, but the email address you supplied was invalid.